Accurate, repeatable, objective measurement of refractive error in small laboratory animals is the methodological foundation of all preclinical myopia research. The gold standard for clinical refraction – subjective manifest refraction with patient feedback – is inherently inapplicable to rodents and birds. Cycloplegic retinoscopy, the classical alternative, requires drug administration (typically atropine or cyclopentolate) to paralyse accommodation before measurement, introducing a pharmacological confound that is particularly problematic in studies evaluating muscarinic agents or investigating accommodation as a myopia-related variable. Manual retinoscopy also demands skilled operator involvement, is relatively slow, and is poorly suited to the dense, repeated measurement protocols that longitudinal myopia studies require.

Eccentric infrared photorefraction resolves these limitations. The technique analyses the asymmetry of the infrared retinal reflex produced by an eccentrically placed light source: in an emmetropic eye the reflex fills the pupil uniformly, while in a myopic or hyperopic eye the reflex is displaced in proportion to the degree of defocus. The Photorefractor applies this principle in an automated format, capturing refractive measurements in alert animals without handling stress, drug administration, or specialist optics training. Multiple measurements per eye can be obtained in rapid succession and averaged, reducing noise from involuntary eye movements. This makes it practical to track each animal in a cohort repeatedly throughout the full course of myopia development, induction, and treatment – at weekly, daily, or even more frequent intervals if the experimental design requires it.

Wen et al. (2024) provided a particularly important demonstration of the longitudinal resolution achievable with Photorefractor, showing that myopia progression follows a nonlinear pathological trajectory with distinct phases rather than a uniform linear increase. This finding has direct implications for study design: different progression phases may respond differently to the same intervention, and measurements taken only at early or late time points may miss critical transitional dynamics entirely. Jiang et al. (2024a) illustrated the dual- measurement power of combining Photorefractor (refraction) with Keratometer (corneal curvature) in a genetic association context, enabling separate structural and functional phenotype quantification from the same measurement session. For the cluster-level discussion of myopia as a research topic spanning multiple disease contexts, see https://stria.tech/application/myopia (coming soon).

Axial elongation – the defining structural feature of myopia – results from biomechanical weakening and active remodelling of the posterior sclera. The scleral ECM is a dynamic tissue whose composition and organisation are continuously regulated by fibroblast activity, protease expression, growth factor signalling, and mechanical stress. Multiple pathways have been implicated in myopic scleral remodelling: TGF-beta and BMP signalling alter collagen fibril diameter and organisation; MMPs and their inhibitors regulate ECM degradation; mTOR-HIF-1alpha signalling links cellular metabolic state to hypoxia-inducible gene expression changes that alter ECM biosynthesis; and lysosomal cysteine proteases including cathepsin H regulate intracellular protein turnover relevant to fibroblast ECM secretion.

A central challenge in this research area is relating molecular observations in the sclera – which require tissue extraction and biochemical or histological analysis – to the functional refractive outcome that constitutes the clinically relevant phenotype. Structural measurements alone (scleral thickness, collagen fibril diameter, ECM protein expression) do not confirm whether the identified pathway alteration actually changed the refractive state of the eye. Photorefractor measurement closes this gap: by obtaining the refractive state before and after genetic, pharmacological, or environmental manipulations targeting scleral biology, researchers can directly establish whether a candidate molecular mechanism is causally sufficient to alter myopia progression, not merely associated with structural changes that occur in its context.

Ciliary muscle function represents an additional structural dimension: the ciliary muscle governs accommodation and may contribute to refractive state through its tension on the lens and its indirect effects on vitreous chamber depth. Gao et al. (2024b) addressed pilocarpine- mediated calcium overload in the ciliary system, using Photorefractor to measure the refractive consequences of pharmacological ciliary stress – data directly relevant to the safety profiling of pilocarpine and related muscarinic agents being investigated as myopia treatments. For the ocular toxicity model context, see also the Ocular & CNS Toxicity Models application page. For the systemic aging context of ciliary senescence, see the Systemic Aging & CNS Decline application page.

Translating a candidate myopia treatment from molecular target identification through preclinical efficacy to clinical development requires a chain of evidence that connects target biology to functional refractive outcome. Structural or molecular endpoints alone – scleral ECM gene expression, choroidal thickness, MMP activity, dopamine levels – do not directly answer the most clinically relevant question: does this intervention actually slow the development of refractive error? Photorefractor measurement closes this gap by providing the refractive diopter value as the functional primary endpoint. Its objectivity (no operator interpretation), speed (multiple measurements per eye per session in alert animals), and repeatability make it ideally suited to dose-response studies, longitudinal tracking of treatment effects, and head-to-head comparison of intervention strategies.

The publications on this pillar span distinct categories of intervention. Cai et al. (2026) exemplify a growth factor signalling approach (BMP2), working at the retina-to-sclera signalling cascade level. Zhang et al. (2024) and Zhao et al. (2025) represent polyphenolic compound treatment using conventional versus nanocarrier-mediated delivery respectively – an instructive comparison of how delivery innovation affects Photorefractor-confirmed refractive efficacy. Jiang et al. (2024b) push the boundary further, evaluating a self-powered electrical stimulation device with both Keratometer (corneal curvature) and Photorefractor (refraction) as dual outcome measures. This diversity of intervention modalities – all anchored by the same Photorefractor endpoint – illustrates the measurement platform’s role as a common translation standard across the myopia drug and device development pipeline.

For detailed coverage of antioxidant and nutritional compounds that also influence myopia progression, see FAQ 5 below. For therapeutic approaches at the structural scleral biology level, see FAQ 2. For the broad myopia cluster page, see https://stria.tech/application/myopia (coming soon).

The retina-to-sclera signalling cascade that governs emmetropisation involves multiple cell types (amacrine cells, Muller glia, RPE cells, choroidal cells, scleral fibroblasts), multiple signalling modalities (neurotransmitters, growth factors, lipid mediators, extracellular vesicles), and multiple molecular layers (transcription, post-transcriptional RNA modification, protein secretion, ECM remodelling). Understanding which nodes in this cascade are causally rate-limiting – and therefore represent the best therapeutic targets – requires systematic perturbation of individual components with refractive outcome confirmation.

A particularly underexplored dimension of myopia regulation is epitranscriptomic control – the post-transcriptional modification of mRNA molecules by chemical tags, particularly N6-methyladenosine (m6A). The m6A methylome regulates mRNA stability, translation efficiency, and splicing in a cell-type-specific manner; its writers (METTL3/14), readers (YTHDF proteins), and erasers (FTO, ALKBH5) are all candidate regulators of the gene expression programmes governing retinal and scleral cell behaviour during myopia development. Zhu et al. (2025) provided direct evidence that ALKBH5, the retinal m6A eraser, influences refractive development when inhibited, with Photorefractor confirming the myopic refractive consequence of this epitranscriptomic perturbation. Lysosomal biology provides another underexplored layer: Mou et al. (2025) demonstrated that cathepsin H deficiency alters ECM proteolysis in the sclera with Photorefractor-confirmed refractive consequences.

The Photorefractor is an essential tool for this molecular research precisely because it provides an objective, continuous quantitative output – spherical equivalent in diopters – that bridges the gap between molecular perturbation and clinical phenotype. Without a functional refractive endpoint, molecular studies in myopia remain mechanistically suggestive but therapeutically unvalidated. With it, researchers can rank the relative contribution of candidate molecular targets to the overall refractive phenotype under standardised conditions.

The myopic eye operates under conditions of elevated oxidative stress relative to the emmetropic eye. Several mechanisms contribute: increased axial length lengthens the path of reactive oxygen species generated by retinal photoreceptor outer segment turnover; scleral hypoxia from stretching and thinning impairs antioxidant defence; and RPE dysfunction associated with progressive myopia reduces the metabolic buffering capacity of this critically protective cell layer. These oxidative conditions accelerate scleral fibroblast senescence, reduce ECM synthesis, and promote photoreceptor and RPE vulnerability – all of which contribute to the progressive nature of high myopia and its complications.

Nutritional and polyphenolic compounds with antioxidant properties are attractive candidates for myopia management precisely because they address this oxidative co-driver through multiple simultaneous mechanisms. Quercetin (a flavonoid) inhibits multiple pro-oxidative and pro-inflammatory pathways including SIRT1-mediated stress responses (Yang 2026) and operates through conventional antioxidant and anti-apoptotic mechanisms (Zhang 2024, FAQ 3). Vitamin E (alpha-tocopherol) acts as a lipid-soluble membrane antioxidant that intercepts lipid peroxidation chain reactions directly. Lutein (a carotenoid) selectively accumulates in the macula and ciliary body and provides both antioxidant and blue-light-filtering protection. Guo et al. (2025) introduced ferroptosis – iron-catalysed lipid peroxidation- driven cell death – as a distinct oxidative pathway with myopia relevance, separate from the classical apoptotic and antioxidant mechanisms addressed by vitamins and polyphenols.

In each case, the Photorefractor provides the essential bridge between compound biochemistry and clinical relevance: demonstrating that oxidative protection translates to a measurable attenuation of myopic refractive shift converts mechanistic antioxidant data into functional evidence for therapeutic potential. This is particularly important for nutritional compounds that require robust functional efficacy data – not merely biochemical markers – to support clinical investigation.

For the aging dimension of oxidative stress and ciliary senescence, see also the Systemic Aging & CNS Decline application page. For the toxicity model context, see the Ocular & CNS Toxicity Models application page.

High myopia (>-6D) is a leading cause of irreversible blindness in East Asian populations and is responsible for a disproportionate share of vision loss attributable to glaucoma, retinal detachment, and myopic maculopathy. The mechanisms linking axial elongation to optic nerve damage are becoming increasingly well characterised. Progressive axial elongation tilts and stretches the optic nerve head and lamina cribrosa, producing mechanical shear forces on RGC axons at the scleral canal that impair axoplasmic transport independently of IOP. The resulting RGC axon vulnerability is thought to explain why high myopes develop normal-tension glaucoma at rates exceeding the general population by a factor of two to three (Ohno-Matsui et al., 2022, Surv. Ophthalmol.).

Studying these complications in rodent and small animal models requires functional endpoints that capture visual circuit integrity – not merely structural or refractive measurements. A Photorefractor measures the refractive state of the eye but provides no information about whether the RGC layer is functioning normally, whether optic nerve axon transport is intact, or whether the visual reflex pathway has been disrupted by stretching or tractional injury. This is where the OptoDrum becomes the relevant instrument: its measurement of spatial visual acuity and contrast sensitivity via the subcortical optomotor reflex provides a non-invasive functional readout of the entire retinofugal pathway from photoreceptors through RGCs to the nucleus of the optic tract – the pathway most directly compromised by high-myopia-related optic nerve stretch. Insignares et al. (2025) demonstrated exactly this in a multi-pathology model of progressive axial elongation, detecting RGC dysfunction and optic nerve damage through functional visual circuit assessment.

For the full body of research on glaucomatous optic nerve neurodegeneration measured with the OptoDrum, see the Glaucoma & Optic Nerve Neurodegeneration application page (20 Striatech publications). For RGC dysfunction across disease contexts, see https://stria.tech/application/retinal-ganglion-cell-dysfunction. For optic nerve damage, see https://stria.tech/application/optic-nerve-damage. For rare inherited eye disorders with overlapping axial elongation features, see the Rare & Inherited CNS and Eye Disorders application page. (Some of these cluster pages may be coming soon.)